Commentary: Crossing the atlantic: The euro-lupus nephritis regimen in North America

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1144-1146

  Wofsy, David ^a   Diamond, Betty ^b   Houssiau, Frédéric A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; MYCOPHENOLATE MOFETIL; RITUXIMAB; ANTIBODY CONJUGATE; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT;

B LYMPHOCYTE; CREATININE BLOOD LEVEL; DRUG DOSE REGIMEN; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE QUALITY; HUMAN; HUMORAL IMMUNE DEFICIENCY; LUPUS ERYTHEMATOSUS NEPHRITIS; NORTH AMERICA; NOTE; PRIORITY JOURNAL; PROTEINURIA; AFRICAN AMERICAN; CAUCASIAN; EUROPE; HISPANIC; INTRAVENOUS DRUG ADMINISTRATION; LUPUS NEPHRITIS; MAINTENANCE CHEMOTHERAPY; PROCEDURES; REMISSION; TREATMENT OUTCOME;

AFRICAN AMERICANS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; EUROPE; EUROPEAN CONTINENTAL ANCESTRY GROUP; HISPANIC AMERICANS; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; INFUSIONS, INTRAVENOUS; LUPUS NEPHRITIS; MAINTENANCE CHEMOTHERAPY; NORTH AMERICA; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84928614448     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39067     Document Type: Note

References (10)

1. Austin HA, 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614-9.
2. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, et al, Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20: 1103-12.
3. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al, for the LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64: 1215-26.
4. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
5. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69: 61-4.
6. The ACCESS Trial Group. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheumatol 2014; 66: 3096-104.
7. Kawabata D, Venkatesh J, Ramanujam M, Davidson A, Grimaldi CM, Diamond B., Enhanced selection of high affinity DNA-reactive B cells following cyclophosphamide treatment in mice. PloS One 2010; 5: e8418.
8. Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011-6.
9. Thien M, Phan TG, Gardam S, Amesbury M, Basten A, Mackay F, et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004; 20: 785-98.
10. Tsuiji M, Yurasov S, Velinzon K, Thomas S, Nussenzweig MC, Wardemann H., A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 2006; 203: 393-400.